{"id":54254,"date":"2026-01-15T21:35:36","date_gmt":"2026-01-15T13:35:36","guid":{"rendered":"https:\/\/flcube.com\/?p=54254"},"modified":"2026-01-15T21:35:38","modified_gmt":"2026-01-15T13:35:38","slug":"nhsa-releases-nrdl-value-assessment-guidelines-prioritizing-8-drug-categories-for-real-world-evaluation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54254","title":{"rendered":"NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real\u2011World Evaluation"},"content":{"rendered":"\n

China\u2019s National Healthcare Security Administration (NHSA)<\/strong> this week released the Series of Guidelines for Real\u2011World Comprehensive NRDL\u2011based Value Assessment of Drugs (Trial)<\/strong>, establishing a systematic framework for evaluating drug value using real\u2011world evidence. The guidelines prioritize eight categories of drugs<\/strong> for assessment and outline how findings will inform National Reimbursement Drug List (NRDL)<\/strong> negotiations and volume\u2011based procurement (VBP) decisions.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>National Healthcare Security Administration (NHSA)<\/td><\/tr>
Document<\/strong><\/td>Series of Guidelines for Real\u2011World Comprehensive NRDL\u2011based Value Assessment of Drugs (Trial)<\/td><\/tr>
Release Date<\/strong><\/td>13\u202fJan\u202f2026<\/td><\/tr>
Status<\/strong><\/td>Trial guidelines open for implementation<\/td><\/tr>
Key Feature<\/strong><\/td>Prioritizes 8 drug categories for real\u2011world comprehensive value assessment<\/td><\/tr>
Purpose<\/strong><\/td>Inform NRDL payment standard adjustments and catalog management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Priority Drug Categories for Assessment<\/h2>\n\n\n\n

The guidelines identify eight circumstances<\/strong> where real\u2011world comprehensive value assessment is prioritized:<\/p>\n\n\n\n

    \n
  1. Conditionally Approved Drugs:<\/strong> Single\u2011arm trial or surrogate endpoint approvals; encourage OS\u2011based assessments<\/li>\n\n\n\n
  2. Generic Drugs Post\u2011Consistency Evaluation:<\/strong> Assess using clinical\/pharmacodynamic endpoints and key safety indicators<\/li>\n\n\n\n
  3. Drug Combinations\/Sequences:<\/strong> Evaluate advantages in effectiveness, safety, economy, and appropriateness vs. existing treatments<\/li>\n\n\n\n
  4. High\u2011Cost\/High\u2011Utilization Drugs:<\/strong> Focus on whether patient outcomes meet expected benefit levels<\/li>\n\n\n\n
  5. Data Integrity Concerns:<\/strong> Drugs questioned by authorities for manipulation or failing to complete confirmatory trials on time<\/li>\n\n\n\n
  6. Off\u2011Label Uses:<\/strong> Therapies used for indications or dosages not in approved labeling or guidelines<\/li>\n\n\n\n
  7. High\u2011Priced Reimbursement List Drugs:<\/strong> Those lacking cost\u2011effectiveness vs. similar drugs<\/li>\n\n\n\n
  8. Other Concerns:<\/strong> Drugs with inappropriate use, major dosage changes per guidelines, or significant public debate on value<\/li>\n<\/ol>\n\n\n\n

    Assessment Outcomes & Incentives<\/h2>\n\n\n\n

    Research findings will be incorporated into NHSA\u2019s real\u2011world comprehensive value assessment database and serve as basis for:<\/p>\n\n\n\n

      \n
    1. New Drugs with Expected Results:<\/strong> Successful NRDL negotiation may receive flexible incentives<\/strong> without disrupting price balance among similar drugs<\/li>\n\n\n\n
    2. Drugs with Insufficient Evidence:<\/strong> Manufacturers can commit to completing assessment; pre\u2011set evidence strength temporarily accepted<\/strong> with flexible incentives, but must submit complete evidence by first renewal or face re\u2011negotiation<\/li>\n\n\n\n
    3. NRDL\u2011Listed Drugs:<\/strong> Encouraged for high\u2011expenditure, rapid\u2011growth, or conditionally approved drugs to proactively conduct assessments alongside post\u2011marketing trials<\/li>\n\n\n\n
    4. Commercial Insurance Drugs:<\/strong> Those seeking NRDL inclusion encouraged to conduct assessments to verify cost\u2011effectiveness<\/li>\n\n\n\n
    5. VBP Candidates:<\/strong> Assessment results can serve as reference for comprehensive scoring, sequencing, and price risk management<\/strong> in procurement rounds<\/li>\n<\/ol>\n\n\n\n

      Market Impact & Strategic Implications<\/h2>\n\n\n\n